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Intracerebroventricular Administration of C-Type
Natriuretic Peptide Suppresses Food Intake via
Activation of the Melanocortin System in Mice
Nobuko Yamada-Goto,1 Goro Katsuura,1 Ken Ebihara,1 Megumi Inuzuka,1 Yukari Ochi,1
Yui Yamashita,1 Toru Kusakabe,1 Akihiro Yasoda,1 Noriko Satoh-Asahara,2 Hiroyuki Ariyasu,1
Kiminori Hosoda,1 and Kazuwa Nakao1
C-type natriuretic peptide (CNP) and its receptor are abundantly
distributed in the brain, especially in the arcuate nucleus (ARC)
of the hypothalamus associated with regulating energy homeosta-
sis. To elucidate the possible involvement of CNP in energy
regulation, we examined the effects of intracerebroventricular
administration of CNP on food intake in mice. The intracerebro-
ventricular administration of CNP-22 and CNP-53 significantly
suppressed food intake on 4-h refeeding after 48-h fasting. Next,
intracerebroventricular administration of CNP-22 and CNP-53 sig-
nificantly decreased nocturnal food intake. The increment of food
intake induced by neuropeptide Y and ghrelin was markedly sup-
pressed by intracerebroventricular administration of CNP-22 and
CNP-53. When SHU9119, an antagonist for melanocortin-3 and
melanocortin-4 receptors, was coadministered with CNP-53, the
suppressive effect of CNP-53 on refeeding after 48-h fasting was
significantly attenuated by SHU9119. Immunohistochemical anal-
ysis revealed that intracerebroventricular administration of CNP-53
markedly increased the number of c-Fos–positive cells in the
ARC, paraventricular nucleus, dorsomedial hypothalamus, ven-
tromedial hypothalamic nucleus, and lateral hypothalamus. In
particular, c-Fos–positive cells in the ARC after intracerebroventric-
ular administration of CNP-53 were coexpressed with a-melanocyte–
stimulating hormone immunoreactivity. These results indicated
that intracerebroventricular administration of CNP induces an
anorexigenic action, in part, via activation of the melanocortin
system. Diabetes 62:1500–1504, 2013
C-type natriuretic peptide (CNP) is a member ofthe natriuretic peptide family and has beendemonstrated to be abundantly present in thebrain, interestingly in discrete hypothalamic
areas, such as the arcuate nucleus (ARC) of the hypo-
thalamus, that play pivotal roles in energy regulation (1–3).
Two predominant molecular forms of CNP in the porcine
brain were reported to be a 22-residue peptide (CNP-22)
and its N-terminally elongated 53-residue peptide (CNP-53)
(1). Moreover, natriuretic peptide receptor-B (NPR-B),
a CNP receptor, is also widely distributed in the brain and
is reported to be abundantly expressed in the ARC of the
hypothalamus (4,5). These findings indicate the possibility
that the brain CNP/NPR-B system may regulate energy
homeostasis.
In the current study, we examined the effects of intra-
cerebroventricular administration of CNP on food intake
induced by refeeding after fasting and by orexigenic pep-
tides, such as neuropeptide Y (NPY) and ghrelin. Also, we
examined the involvement of the melanocortin system in
the CNP actions.
RESEARCH DESIGN AND METHODS
Animals and diets. Male C57BL/6J mice (6 weeks old) obtained from Japan
SLC (Shizuoka, Japan) were housed in plastic cages in a room kept at a room
temperature of 23 6 1°C and a 12:12-h light–dark cycle (lights turned on at
9:00 A.M.). The mice had ad libitum access to water and food (CE-2; CLEA
Japan, Tokyo, Japan). All experiments were performed at 10 weeks of age in
accordance with the guidelines established by the Institutional Animal In-
vestigation Committee at Kyoto University and the United States National
Institutes of Health Guide for the Care and Use of Laboratory Animals. Every
effort was made to optimize comfort and to minimize the use of animals.
Peptides. CNP-22, CNP-53, ghrelin, and NPY were purchased from Peptide
Institute (Osaka, Japan). SHU9119 was purchased from Bachem AG (Buben-
dorf, Switzerland).
Intracerebroventricular injection. Intracerebroventricular injection was
performed according to our previous report (6).
Measurement of food intake
Fasting-refeeding.Micewere fasted for 48 h and then refed for 4 h. Water was
available ad libitum during the experiments. The intracerebroventricular or
intraperitoneal administration of CNP-22 or CNP-53 was performed just before
refeeding. Food intake was measured for 4 h of refeeding. At the end of
experiments, the hypothalamus was collected for examination of the expres-
sions of mRNA for neuropeptides (7).
Nocturnal food intake. To assess the effect of intracerebroventricular ad-
ministration of CNP-22 or CNP-53 on nocturnal food intake, peptides were
injected intracerebroventricularly 1 h before the beginning of the dark phase.
Food intake was measured for 15 h after intracerebroventricular injection.
Water was available ad libitum during the experiments.
Food intake induced by NPY and ghrelin. The experiments were per-
formed from 11:00 A.M. to 3:00 P.M. CNP-22 or CNP-53 was intracerebro-
ventricularly administrated just before intracerebroventricular injection of
NPY (5 nmol/mouse) or intraperitoneal injection of ghrelin (100 nmol/kg).
Food intake was measured for 4 h after peptide injection. In these experi-
ments, food and water were available ad libitum.
PCR. The extraction of mRNA and quantitative real-time RT-PCR were per-
formed according to our previous report (8). Primers for preopiomelanocortin,
cocaine and amphetamine-related peptide, NPY, agouti gene-related peptide
(AgRP) and glyceraldehyde 3-phosphate dehydrogenase are shown in Sup-
plementary Table 1.
Immunohistochemistry for c-Fos and a-MSH in the hypothalamus. The
immunohistochemical methods and the stereotaxic coordinates for the hy-
pothalamic nuclei were based on our previous report (6). Briefly, mice were
anesthetized with pentobarbital at 1 h after intracerebroventricular injection
of CNP-53 (1.5 nmol/mouse) and perfused with 50 mL 0.1 mol/L PBS, followed
by 50 mL ice-cold 4% paraformaldehyde in 0.1 mol/L PBS. Sections of 30-mm
thickness were cut with a cryostat. According to the mouse brain atlas (9),
cross-sections were selected in correspondence to 21.70 mm [ARC, lateral hy-
pothalamus (LH), dorsomedial hypothalamus (DMH), ventromedial hypothalamic
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nucleus (VMH)] and to 20.82 mm [paraventricular nucleus (PVN)], relative to
bregma. For c-Fos and a-melanocyte–stimulating hormone (a-MSH) protein
staining, the sections were incubated with antic-Fos rabbit antibody (Ab-5;
1:5,000; Oncogene Science, Cambridge, MA) and antia-MSH sheep antibody
(AB5087; 1:10,000; EMD Millipore, Billerica, MA), respectively. The antibody
was detected using the Vectastain ABC Elite kit (PK-6101; Vector Laborato-
ries, Burlingame, CA) and a diaminobenzidine substrate kit (SK-4100; Vector
Laboratories) was used for visualization. The second antibodies for fluores-
cence visualization used were goat anti-rabbit488 (A11008; 1:200; Life Tech-
nologies, Carlsbad, CA) for antic-Fos rabbit antibody and goat anti-sheep546
(A21098; 1:200; Life Technologies) for antia-MSH sheep antibody.
Data analysis. All values are given as the mean 6 SEM. Statistical analysis of
the data were performed by ANOVA, followed by the Tukey-Kramer test.
Statistical significance was defined as P , 0.05.
RESULTS
Effects of intracerebroventricular administration of
CNP-22 and CNP-53 on food intake at refeeding after
fasting. The intracerebroventricular administration of
CNP-22 (1.5 and 4.5 nmol/mouse) and CNP-53 (1.5 nmol/
mouse) significantly suppressed food intake during 4-h
refeeding after 48-h fasting in comparison with data from
saline-treated mice (Fig. 1A). In this experiment, CNP-53
(1.5 nmol), but not other treatments, induced significant
reduction of body weight compared with saline treatment
(Supplementary Table 2). The mRNA expressions of pre-
opiomelanocortin and cocaine and amphetamine-related
peptide significantly decreased, and the mRNA expres-
sions of NPY and AgRP significantly increased after
refeeding compared with control animals (Supplementary
Fig. 1). The intracerebroventricular administration of CNP-53
did not influence the mRNA expressions of these neuro-
peptides in the hypothalamus (Supplementary Fig. 1).
Next, the peripheral action of CNP on food intake was exam-
ined when a 10-fold greater dose than intracerebroventricular
injection of each CNP was intraperitoneally adminis-
tered. The intraperitoneal administrations of CNP-22
(1.5 mmol/kg) and CNP-53 (0.5 mmol/kg) did not change the
food intake during 4-h refeeding after 48-h fasting (Fig. 1B),
nor were there changes in body weight (Supplementary
Table 3).
The intracerebroventricular administrations of CNP-22
(4.5 nmol/mouse) and CNP-53 (1.5 nmol/mouse) at 1 h
before the start of the dark phase significantly suppressed
nocturnal food intake compared with saline treatment
(Fig. 1C).
Effect of intracerebroventricular administration of
CNP-22 and CNP-53 on NPY-induced and ghrelin-
induced food intake. When CNP-22 (4.5 nmol/mouse)
and CNP-53 (1.5 nmol/mouse) were concomitantly ad-
ministered intracerebroventricularly with NPY, they sig-
nificantly suppressed the food intake induced by NPY
compared with that of saline treatment (Fig. 2A). When
CNP-22 (4.5 nmol/mouse) and CNP-53 (1.5 nmol/mouse)
were administered intracerebroventricularly with ghrelin,
they significantly suppressed the food intake induced by
ghrelin compared with that of saline treatment (Fig. 2B).
Effect of melanocortin receptor antagonist, SHU9119,
on the anorectic effect of CNP. To examine its in-
volvement in the anorectic effect of CNP, SHU9119 was
administered intracerebroventricularly together with
CNP-53 (1.5 nmol/mouse). SHU9119 (1 nmol/mouse) sig-
nificantly attenuated the suppressive action of CNP-53 on
the food intake during 4-h refeeding after 48-h fasting,
whereas SHU9119 itself significantly enhanced the increase
of food intake in comparison with mice administered saline
treatment (Fig. 3).
FIG. 1. Effects of CNP on refeeding after fasting. A: Effects of intra-
cerebroventricular administration of CNP-22 (0.5, 1.5, and 4.5 nmol/
mouse) and CNP-53 (0.5 and 1.5 nmol/mouse) on 4-h refeeding after 48-h
fasting in mice. Food intake was observed for 4 h after refeeding.
B: Effects of intraperitoneal administration of CNP-22 (1.5 mmol/kg) and
CNP-53 (0.5 mmol/kg) on 4-h refeeding after 48-h fasting in mice. Food
intake was observed for 4 h after refeeding. C: Effects of intrace-
rebroventricular administration of CNP-22 (4.5 nmol/mouse) and CNP-53
(1.5 nmol/mouse) on nocturnal food intake in mice. Food intake was ob-
served for 15 h after intracerebroventricular injection. Data represent
mean 6 SEM. The number of mice is given in parentheses. Significant
differences: *P < 0.05, **P < 0.01.
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c-Fos–immunoreactive cells in the hypothalamus af-
ter intracerebroventricular administration of CNP.
To understand the neuronal pathway involved in the ano-
rectic actions of CNP, the expression of c-Fos, one of the
markers of neuronal activation, was monitored by immu-
nohistochemical examination at 1 h after intracerebroven-
tricular injection of CNP-53 (1.5 nmol/mouse). The numbers
of c-Fos–immunoreactive cells in the ARC, PVN, and DMH
were predominantly increased after intracerebroventricular
injection of CNP-53 in comparison with saline treatment
(Fig. 4A). The c-Fos–positive cells were also moderately
increased in the VMH and LH (Fig. 4A). Next, we examined
whether c-Fos immunoreactivity coexisted with a-MSH–
containing cells. In the ARC of saline-treated mice, only a
few a-MSH–immunoreactive cells showed weak c-Fos im-
munoreactivity (Fig. 4B). However, c-Fos–immunoreactive
cells that increased with intracerebroventricular adminis-
tration of CNP-53 in the ARC expressed a large amount of
a-MSH immunoreactivity (Fig. 4B).
DISCUSSION
The current study demonstrated that intracerebroventri-
cular administration of CNP-22 and CNP-53, but not in-
traperitoneal injection, led to significant reduction of food
intake induced by fasting–refeeding. This reduction was in-
hibited by the melanocortin-3 receptor (MC3R)/melanocortin-
4 receptor (MC4R) antagonist SHU9119. In addition, CNP
significantly suppressed nocturnal food intake and orexi-
genic actions induced by NPY and ghrelin. The immuno-
histochemical study revealed that intracerebroventricular
administration of CNP-53 increased the number of c-Fos–
expressing cells containing a-MSH in the hypothalamus.
These findings indicated that the intracerebroventricular
administration of CNP exhibits anorexigenic actions par-
tially via activation of the melanocortin system, although
the doses of CNP used in the current study could be phar-
macological doses.
The hypothalamus is considered to be an important re-
gion in regulating energy homeostasis. In particular, the ARC
in the hypothalamus contains both an orexigenic peptide,
NPY, and an anorexigenic peptide, a-MSH, and is postu-
lated to be involved in the first-order regulation of food
intake. Synthetic MC3R/MC4R agonists, melanotan II, and
[Nle4-D-Phe7]–a-MSH completely blocked food deprivation–
induced increase in food intake as well as the food in-
take stimulated by intracerebroventricular administration
of NPY (10,11). Regarding the reciprocal interactions
of a-MSH and NPY, melanocortin neurons in the ARC
project to the PVN (12). In the current study, intracere-
broventricular administration of CNP significantly sup-
pressed food intake after fasting, which was antagonized
by SHU9119. Our results also showed that CNP suppressed
NPY-induced food intake. Taken together, these findings
indicate that CNP exhibits anorexigenic actions via acti-
vation of MC3R/MC4R downstream signaling. However,
mRNA expressions of preopiomelanocortin, cocaine and
amphetamine-related peptide, NPY, and AgRP in the hy-
pothalamus after the intracerebroventricular injection of
CNP-53 in fasting–refeeding experiment did not change
compared with those after saline. The reason for this
FIG. 2. Effects of CNP-22 and CNP-53 on food intake induced by NPY
and ghrelin. A: Effects of intracerebroventricular administration of
CNP-22 (4.5 nmol/mouse) and CNP-53 (1.5 nmol/mouse) on NPY-
induced (5 nmol/mouse, intracerebroventricular) food intake in mice.
Food intake was observed for 4 h after coadministration of NPY and
CNP. B: Effects of intracerebroventricular administration of CNP-22
(4.5 nmol/mouse) and CNP-53 (1.5 nmol/mouse) on ghrelin-induced
(100 nmol/kg, intraperitoneal) food intake in mice. Food intake was
observed for 4 h after coadministration of ghrelin and CNP. Data rep-
resent mean 6 SEM. The number of mice is given in parentheses. Sig-
nificant differences: *P < 0.05, **P < 0.01.
FIG. 3. Effects of intracerebroventricular administration of CNP-53
(1.5 nmol/mouse) and SHU9119 (1 nmol/mouse) on refeeding after 48-h
fasting in mice. Food intake was observed for 4 h after refeeding. Data
represent mean 6 SEM. The number of mice is given in parentheses.
Significant differences: *P < 0.05, **P < 0.01.
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discrepancy may lie in the experimental condition, time
course, and regional specificity. To clarify this discrep-
ancy, further examinations will be required.
This study demonstrated that the intracerebroventri-
cular administration of CNP significantly suppressed the
nocturnal food intake. Robust feeding during the nocturnal
phase of the daily light–dark cycle was demonstrated to be
attributed to the upregulation of NPY and its receptors (13).
These findings indicate that CNP may decrease food intake
in the nocturnal phase via suppression of NPY action.
In the current study, CNP significantly suppressed the
increase in food intake induced by ghrelin, an orexigenic
hormone secreted by the stomach (14). NPR-B, a CNP
receptor, has been identified in appetite-regulating regions,
such as the ARC, VMH, PVN, DMH, and LH (15). The
systemic administration of ghrelin significantly increased
NPY and AgRP expression in the ARC of the hypothalamus
in fed and fasted rats (15), resulting in hyperphagia. The
intracerebroventricular injection of melanotan II caused
a significant decrease in ghrelin-induced food intake (16).
These findings suggest that the actions of ghrelin are
modulated by a-MSH and NPY systems. Furthermore,
plasma ghrelin and hypothalamic ghrelin receptor mRNA
expression are reported to be increased after fasting
(17,18). These findings suggest the possibility that intra-
cerebroventricular administration of CNP activates the
melanocortin system, which subsequently inhibits the ac-
tion of NPY, resulting in a reduced increase of food intake
induced by ghrelin.
To assess which hypothalamic nucleus is involved in the
anorexigenic action of CNP, a marker for neuronal activity,
c-Fos expression in the hypothalamus was examined after
intracerebroventricular administration of CNP-53. The intra-
cerebroventricular administration of CNP-53 significantly
increased the number of c-Fos–expressing cells in several
hypothalamic nuclei, such as ARC, PVN, DMH, VMH, and LH,
indicating that CNP-53 directly or indirectly stimulates neu-
rons in these hypothalamic nuclei. Especially in the ARC, the
result was an increased number of c-Fos–immunoreactive
cells containing a-MSH immunoreactivity, indicating that
CNP stimulates a-MSH–containing neurons. This possibility
is supported by the finding that the suppressive action of
CNP-53 on food intake was blocked by concomitant admin-
istration of SHU9119, an MC3R/MC4R antagonist.
The current study has demonstrated the anorexigenic
action of intracerebroventricular administration of CNP
via activation of the melanocortin system. To define the
precise effect of CNP in the brain on food intake, further
investigation using mice with inducible brain-specific de-
letion of CNP or NPR-B/NPR-C will be required.
From the present findings, we postulate the possible
mechanism for anorexigenic action of exogenous CNP to
be as follows: CNP directly or indirectly acts on a-MSH–
containing neurons and subsequently stimulates a-MSH
release, resulting in suppression of food intake induced by
NPY and ghrelin. This possible mechanism may apply to
the suppressive effects of CNP on food intake after fasting
and in the nocturnal phase. Further work is needed to
define the pathophysiological significance of brain CNP in
regulation of food intake.
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